Peter Gibbs

Peter Gibbs's AcademicInfluence.com Rankings

Peter Gibbs

Computer Science

#6617

World Rank

#6975

Historical Rank

Algorithms

#241

World Rank

#244

Historical Rank

Machine Learning

#2207

World Rank

#2235

Historical Rank

Artificial Intelligence

#2475

World Rank

#2516

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Peter Gibbs's Degrees

Bachelors Mathematics University of Oxford

Similar Degrees You Can Earn

Best Online Bachelor's in Math 2025

Why Is Peter Gibbs Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Peter Gibbs's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Detection and localization of surgically resectable cancers with a multi-analyte blood test (2018) (1556)
Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours (2013) (1136)
Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer (2016) (922)
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. (2020) (802)
Cancer classification using the Immunoscore: a worldwide task force (2012) (719)
Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer (2011) (623)
Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer (2015) (518)
Effect of Aspirin on All‐Cause Mortality in the Healthy Elderly (2018) (511)
Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. (2015) (461)
Metastasis-Associated Gene Expression Changes Predict Poor Outcomes in Patients with Dukes Stage B and C Colorectal Cancer (2009) (409)
Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer. (2006) (389)
Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers (2017) (387)
Introduction to Radiomics (2020) (357)
Effect of Aspirin on Disability‐free Survival in the Healthy Elderly (2018) (318)
Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. (2007) (311)
Tolerance of whole-genome doubling propagates chromosomal instability and accelerates cancer genome evolution. (2014) (310)
Textural analysis of contrast‐enhanced MR images of the breast (2003) (288)
Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer. (2019) (282)
Correlation of ADC and T2 Measurements With Cell Density in Prostate Cancer at 3.0 Tesla (2009) (278)
SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer. (2016) (269)
SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer. (2013) (266)
First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials (2017) (240)
First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials (2017) (240)
Correlation of diffusion‐weighted magnetic resonance data with cellularity in prostate cancer (2009) (239)
Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H). (2014) (215)
Optimizing targeted therapeutic development: Analysis of a colorectal cancer patient population with the BRAFV600E mutation (2011) (214)
Comparison of quantitative T2 mapping and diffusion‐weighted imaging in the normal and pathologic prostate (2001) (213)
Tumour volume determination from MR images by morphological segmentation. (1996) (212)
Role of dynamic contrast enhanced MRI in monitoring early response of locally advanced breast cancer to neoadjuvant chemotherapy (2005) (210)
Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study (2018) (207)
Multiple Common Susceptibility Variants near BMP Pathway Loci GREM1, BMP4, and BMP2 Explain Part of the Missing Heritability of Colorectal Cancer (2011) (204)
Study design of ASPirin in Reducing Events in the Elderly (ASPREE): a randomized, controlled trial. (2013) (195)
KRAS Mutation Is Associated with Lung Metastasis in Patients with Curatively Resected Colorectal Cancer (2011) (194)
Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes (2017) (185)
Texture analysis in assessment and prediction of chemotherapy response in breast cancer (2013) (179)
Analysis of colorectal cancers in British Bangladeshi identifies early onset, frequent mucinous histotype and a high prevalence of RBFOX1 deletion (2013) (177)
Diffusion‐weighted imaging of normal and malignant prostate tissue at 3.0T (2006) (168)
Diffusion Imaging of the Prostate at 3.0 Tesla (2006) (160)
Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 Study. (2020) (159)
PIK3CA, BRAF, and PTEN Status and Benefit from Cetuximab in the Treatment of Advanced Colorectal Cancer—Results from NCIC CTG/AGITG CO.17 (2013) (143)
Cytosine methylation profiling of cancer cell lines (2008) (137)
BRAF V600E Mutant Colorectal Cancer Subtypes Based on Gene Expression (2016) (137)
Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial. (2009) (132)
Survival in stage II/III colorectal cancer is independently predicted by chromosomal and microsatellite instability, but not by specific driver mutations (2013) (131)
Early detection of cancer: past, present, and future. (2015) (131)
Prognostic Potential of Circulating Tumor DNA Measurement in Postoperative Surveillance of Nonmetastatic Colorectal Cancer. (2019) (123)
Different APC genotypes in proximal and distal sporadic colorectal cancers suggest distinct WNT/β-catenin signalling thresholds for tumourigenesis (2012) (122)
Baseline Characteristics of Participants in the ASPREE (ASPirin in Reducing Events in the Elderly) Study (2017) (117)
Dynamic contrast‐enhanced MRI texture analysis for pretreatment prediction of clinical and pathological response to neoadjuvant chemotherapy in patients with locally advanced breast cancer (2014) (116)
Comparison of ECOG/WHO performance status and ASA score as a measure of functional status. (2015) (115)
PIK3CA and PTEN Gene and Exon Mutation-Specific Clinicopathologic and Molecular Associations in Colorectal Cancer (2013) (114)
Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer. (2022) (114)
A prospective evaluation of treatment with Selective Internal Radiation Therapy (SIR-spheres) in patients with unresectable liver metastases from colorectal cancer previously treated with 5-FU based chemotherapy (2005) (112)
High‐speed multislice T1 mapping using inversion‐recovery echo‐planar imaging (1990) (109)
Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. (2022) (102)
Chemotherapy dosing strategies in the obese, elderly, and thin patient: results of a nationwide survey. (2008) (99)
Radiotherapy in the management of solitary extramedullary plasmacytoma (2005) (98)
DNA Copy-Number Alterations Underlie Gene Expression Differences between Microsatellite Stable and Unstable Colorectal Cancers (2008) (95)
MiRNA‐362‐3p induces cell cycle arrest through targeting of E2F1, USF2 and PTPN1 and is associated with recurrence of colorectal cancer (2013) (95)
Dynamic contrast‐enhanced MRI in the differentiation of breast tumors: User‐defined versus semi‐automated region‐of‐interest analysis (1999) (90)
A systematic review on the safety and efficacy of yttrium-90 radioembolization for unresectable, chemorefractory colorectal cancer liver metastases (2014) (85)
Radiotherapy treatment planning of brain tumours using MRI alone. (1998) (85)
Echo planar imaging of the human fetus in utero at 0.5 T. (1990) (80)
Two phase I studies of low dose recombinant human IL-12 with Melan-A and influenza peptides in subjects with advanced malignant melanoma. (2003) (80)
PHLDA1 expression marks the putative epithelial stem cells and contributes to intestinal tumorigenesis. (2011) (75)
Differentiation of benign and malignant sub-1 cm breast lesions using dynamic contrast enhanced MRI. (2004) (75)
Prospective study of treatment with selective internal radiation therapy spheres in patients with unresectable primary or secondary hepatic malignancies (2005) (73)
Radioembolization in combination with systemic chemotherapy as first-line therapy for liver metastases from colorectal cancer. (2011) (73)
Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer. (2019) (72)
Feasibility of conducting a primary prevention trial of low‐dose aspirin for major adverse cardiovascular events in older people in Australia: results from the ASPirin in Reducing Events in the Elderly (ASPREE) pilot study (2008) (71)
Real‐time flow measurements using echo‐planar imaging (1991) (68)
The survival outcome of patients with metastatic colorectal cancer based on the site of metastases and the impact of molecular markers and site of primary cancer on metastatic pattern (2018) (68)
Long-Term Outcomes of Patients with Localized Rectal Cancer Treated with Chemoradiation or Radiotherapy Alone Because of Medical Inoperability or Patient Refusal (2007) (63)
Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: the SIRFLOX study (2014) (61)
Blood-Based Protein Biomarker Panel for the Detection of Colorectal Cancer (2015) (59)
An inverse stage‐shift model to estimate the excess mortality and health economic impact of delayed access to cancer services due to the COVID‐19 pandemic (2020) (58)
Optimizing the Outcome for Patients With Rectal Cancer (2003) (58)
Repeatability of echo-planar-based diffusion measurements of the human prostate at 3 T. (2007) (57)
Pediatric Melanoma: Are Recent Advances in the Management of Adult Melanoma Relevant to the Pediatric Population (2000) (56)
Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study (2021) (55)
Functional Screening Identifies miRNAs Influencing Apoptosis and Proliferation in Colorectal Cancer (2014) (54)
Analysis of local chronic inflammatory cell infiltrate combined with systemic inflammation improves prognostication in stage II colon cancer independent of standard clinicopathologic criteria (2016) (54)
Breast lesion analysis of shape technique: Semiautomated vs. manual morphological description (2006) (54)
Prognostic significance of postsurgery circulating tumor DNA in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies (2020) (53)
Preoperative Chemoradiation for Rectal Cancer Causes Prolonged Pudendal Nerve Terminal Motor Latency (2006) (52)
Cardiac metastases from malignant melanoma (1999) (50)
Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based series (2018) (49)
Analysis of Prostate DCE-MRI: Comparison of Fast Exchange Limit and Fast Exchange Regimen Pharmacokinetic Models in the Discrimination of Malignant From Normal Tissue (2009) (49)
Echo‐planar imaging of the human fetus in utero (1990) (49)
Peripheral enhancement and spatial contrast uptake heterogeneity of primary breast tumours: quantitative assessment with dynamic MRI. (1998) (49)
Radiomic features of glucose metabolism enable prediction of outcome in mantle cell lymphoma (2019) (47)
A phase II study of neoadjuvant biochemotherapy for stage III melanoma (2002) (47)
Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutation (2015) (47)
Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localised pancreatic cancer. (2019) (47)
Pretreatment Prognostic Value of Dynamic Contrast-Enhanced Magnetic Resonance Imaging Vascular, Texture, Shape, and Size Parameters Compared With Traditional Survival Indicators Obtained From Locally Advanced Breast Cancer Patients (2016) (46)
Prolonged monitoring of the upper gastrointestinal tract using echo planar magnetic resonance imaging. (1993) (46)
Initial impact of Australia's National Bowel Cancer Screening Program (2009) (46)
Hyaluronan-Irinotecan improves progression-free survival in 5-fluorouracil refractory patients with metastatic colorectal cancer: a randomized phase II trial (2010) (46)
Patient age and comorbidity are major determinants of adjuvant chemotherapy use for stage III colon cancer in routine clinical practice. (2008) (46)
Clinical trial participation and outcome for patients with glioblastoma: Multivariate analysis from a comprehensive dataset (2013) (46)
Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17. (2013) (45)
Lymphocytic response to tumour and deficient DNA mismatch repair identify subtypes of stage II/III colorectal cancer associated with patient outcomes (2018) (45)
A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer (2014) (45)
Comorbidity, age and overall survival in cetuximab-treated patients with advanced colorectal cancer (ACRC)--results from NCIC CTG CO.17: a phase III trial of cetuximab versus best supportive care. (2011) (44)
Impact of Primary Tumor Site on Bevacizumab Efficacy in Metastatic Colorectal Cancer. (2016) (43)
Use of multiple reaction monitoring for multiplex analysis of colorectal cancer‐associated proteins in human feces (2011) (42)
Primary Tumor Resection in Patients With Metastatic Colorectal Cancer Is Associated With Reversal of Systemic Inflammation and Improved Survival. (2015) (42)
Quality of pathology reporting impacts on lymph node yield in colon cancer. (2007) (41)
Targeted therapy for metastatic colorectal cancer (2018) (40)
Management of primary cutaneous melanoma of the head and neck: The University of Colorado experience and a review of the literature (2001) (39)
Value of database linkage: are patients at risk of familial colorectal cancer being referred for genetic counselling and testing? (2008) (39)
Caution is required before recommending routine carcinoembryonic antigen and imaging follow-up for patients with early-stage colon cancer. (2009) (38)
SIRFLOX: Randomized phase III trial comparing first-line mFOLFOX6 {+/-} bevacizumab (bev) versus mFOLFOX6 + selective internal radiation therapy (SIRT) {+/-} bev in patients (pts) with metastatic colorectal cancer (mCRC). (2015) (37)
Assessing aneuploidy with repetitive element sequencing (2019) (37)
Wild-type APC predicts poor prognosis in microsatellite-stable proximal colon cancer (2015) (36)
A simple solution for reducing artefacts due to conductive and dielectric effects in clinical magnetic resonance imaging at 3T. (2007) (36)
KEYNOTE-177: Phase III randomized study of pembrolizumab versus chemotherapy for microsatellite instability-high advanced colorectal cancer. (2021) (35)
MACROD2 Haploinsufficiency Impairs Catalytic Activity of PARP1 and Promotes Chromosome Instability and Growth of Intestinal Tumors. (2018) (35)
Squamous cell carcinoma arising in a giant condyloma acuminatum (Buschke-Lowenstein tumour). (2005) (34)
Newer strategies for effective evaluation of primary melanoma and treatment of stage III and IV disease. (2000) (33)
Primary breast abnormalities: selective pixel sampling on dynamic gadolinium-enhanced MR images. (1998) (33)
Impact of Emergent Circulating Tumor DNA RAS Mutation in Panitumumab-Treated Chemoresistant Metastatic Colorectal Cancer (2018) (33)
Developing a national database for metastatic colorectal cancer management: perspectives and challenges (2013) (33)
Safety of selective internal radiation therapy (SIRT) with yttrium-90 microspheres combined with systemic anticancer agents: expert consensus. (2017) (32)
ctDNA and Adjuvant Therapy for Colorectal Cancer: Time to Re-Invent Our Treatment Paradigm (2021) (31)
The rapidly escalating cost of treating colorectal cancer in Australia (2016) (30)
MRI-based machine learning radiomics can predict HER2 expression level and pathologic response after neoadjuvant therapy in HER2 overexpressing breast cancer (2020) (30)
Molecular and Cellular Pathobiology SMAD 2 , SMAD 3 and SMAD 4 Mutations in Colorectal Cancer (2013) (30)
Re‐inventing the randomized controlled trial in medical oncology: The registry‐based trial (2018) (29)
Chelator free gallium-68 radiolabelling of silica coated iron oxide nanorods via surface interactions. (2015) (29)
Nevi and Melanoma: Lessons from Turner’s Syndrome (2001) (29)
Open-label phase I trial of vandetanib in combination with mFOLFOX6 in patients with advanced colorectal cancer (2009) (28)
A Pilot Human Evaluation of a Formulation of Irinotecan and Hyaluronic Acid in 5-Fluorouracil-Refractory Metastatic Colorectal Cancer Patients (2008) (28)
Final overall survival for the phase III KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC). (2021) (28)
Characterization of Sub‐1 cm Breast Lesions Using Radiomics Analysis (2019) (28)
Bending the cost curve in cancer care. (2011) (27)
Evaluation of Emergent Mutations in Circulating Cell-Free DNA and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Treated with Panitumumab in the ASPECCT Study (2018) (27)
Ultrafast dynamic contrast-enhanced breast MRI may generate prognostic imaging markers of breast cancer (2020) (26)
Comparing oncological outcomes of laparoscopic versus open surgery for colon cancer: Analysis of a large prospective clinical database (2015) (25)
Preoperative investigations for metastatic staging of colon and rectal cancer across multiple centres – what is current practice? (2009) (25)
A Phase III, Randomized, Double‐Blind, Placebo‐Controlled Trial of Pegfilgrastim in Patients Receiving First‐Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti‐VEGF Evaluation Study (PAVES) (2017) (24)
[18F]FDG-PET/CT Radiomics for Prediction of Bone Marrow Involvement in Mantle Cell Lymphoma: A Retrospective Study in 97 Patients (2020) (24)
Girdin (GIV) Expression as a Prognostic Marker of Recurrence in Mismatch Repair–Proficient Stage II Colon Cancer (2016) (24)
Impact of anastomotic leak on recurrence and survival after colorectal cancer surgery: a BioGrid Australia analysis (2018) (24)
TOWARDS ESTABLISHING A NATIONAL COLORECTAL CANCER DATABASE: LESSONS LEARNT FROM BIO21 MOLECULAR MEDICINE INFORMATICS MODEL (2008) (24)
Effect of Primary Tumor Side on Survival Outcomes in Untreated Patients With Metastatic Colorectal Cancer When Selective Internal Radiation Therapy Is Added to Chemotherapy: Combined Analysis of Two Randomized Controlled Studies (2018) (24)
Mapping EORTC-QLQ-C30 to EQ-5D-3L in patients with colorectal cancer (2017) (23)
Carcinoma of the anal canal: a local experience and review of the literature (2004) (23)
Secondary technical resectability of colorectal cancer liver metastases after chemotherapy with or without selective internal radiotherapy in the randomized SIRFLOX trial (2019) (23)
Relative telomere lengths in tumor and normal mucosa are related to disease progression and chromosome instability profiles in colorectal cancer (2016) (23)
Defining key design elements of registry-based randomised controlled trials: a scoping review (2020) (23)
Differentiation between subcentimeter carcinomas and benign lesions using kinetic parameters derived from ultrafast dynamic contrast-enhanced breast MRI (2019) (23)
Prognostic value of MACC1 and proficient mismatch repair status for recurrence risk prediction in stage II colon cancer patients: the BIOGRID studies (2017) (23)
Protocol for Combined Analysis of FOXFIRE, SIRFLOX, and FOXFIRE-Global Randomized Phase III Trials of Chemotherapy +/- Selective Internal Radiation Therapy as First-Line Treatment for Patients With Metastatic Colorectal Cancer (2017) (22)
A phase II study of biochemotherapy for the treatment of metastatic malignant melanoma (2000) (22)
Dose rounding of chemotherapy in colorectal cancer: An analysis of clinician attitudes and the potential impact on treatment costs (2010) (22)
Refinement of the associations between risk of colorectal cancer and polymorphisms on chromosomes 1q41 and 12q13.13 (2011) (22)
ORIGINAL ARTICLE: Linking data from hospital and cancer registry databases: should this be standard practice? (2010) (22)
Phase I and Pharmacokinetic Evaluation of Intravenous Hyaluronic Acid in Combination with Doxorubicin or 5-Fluorouracil (2005) (22)
Detection of low-frequency DNA variants by targeted sequencing of the Watson and Crick strands (2021) (21)
Audit of postoperative chemoradiotherapy as adjuvant therapy for resected gastroesophageal adenocarcinoma: an Australian multicentre experience (2004) (21)
Ultrafast magnetic resonance scanning of the liver with echo-planar imaging. (1990) (21)
Overall survival analysis of the FOXFIRE prospective randomized studies of first-line selective internal radiotherapy (SIRT) in patients with liver metastases from colorectal cancer. (2017) (21)
The Genes and Genetics of Malignant Melanoma (2002) (20)
Stage‐based Variation in the Effect of Primary Tumor Side on All Stages of Colorectal Cancer Recurrence and Survival (2018) (20)
Overview of biomarkers in metastatic colorectal cancer: tumour, blood and patient-related factors. (2013) (20)
Minkowski functionals: An MRI texture analysis tool for determination of the aggressiveness of breast cancer (2016) (20)
Survival impact of the Australian National Bowel Cancer Screening Programme (2016) (20)
BioGrid Australia facilitates collaborative medical and bioinformatics research across hospitals and medical research institutes by linking data from diverse disease and data types (2011) (20)
Pancreatic cancer - current management. (2006) (20)
Multiparametric Integrated 18F-FDG PET/MRI-Based Radiomics for Breast Cancer Phenotyping and Tumor Decoding (2021) (19)
Phase II trial of selective internal radiation therapy and systemic chemotherapy for liver-predominant metastases from pancreatic adenocarcinoma (2015) (19)
Improved characterization of sub-centimeter enhancing breast masses on MRI with radiomics and machine learning in BRCA mutation carriers (2020) (19)
Observation of cerebrospinal fluid flow with echo-planar magnetic resonance imaging. (1991) (19)
Multidisciplinary Management of Locally Advanced Rectal Cancer--An Evolving Landscape? (2015) (19)
Recurrence in patients with stage I colorectal cancer (2016) (18)
ECHO-PLANAR MAGNETIC RESONANCE IMAGING IN ABNORMAL PREGNANCIES (1989) (18)
Serial circulating tumor DNA (ctDNA) analysis as a prognostic marker and a real-time indicator of adjuvant chemotherapy (CT) efficacy in stage III colon cancer (CC). (2018) (18)
Treatment and outcomes of metastatic colorectal cancer in Australia: defining differences between public and private practice (2015) (18)
Patterns of care and outcomes for elderly patients with metastatic colorectal cancer in Australia. (2015) (18)
MAGE‐12 and MAGE‐6 are frequently expressed in malignant melanoma (2000) (18)
Circulating tumor DNA (ctDNA) as a marker of recurrence risk in stage II colon cancer (CC). (2014) (18)
Preliminary analysis of the cost‐effectiveness of the National Bowel Cancer Screening Program: demonstrating the potential value of comprehensive real world data (2012) (17)
An Australian translational Study to evaluate the prognostic role of inflammatory markers in patients with metastatic ColorEctal caNcer Treated with bevacizumab (Avastin™) [ASCENT] (2013) (17)
Predictors of clinic non‐attendance: opportunities to improve patient outcomes in colorectal cancer (2010) (17)
Efficacy, Tolerability, and Biomarker Analyses of Once‐Every‐2‐Weeks Cetuximab Plus First‐Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild‐Type Metastatic Colorectal Cancer: The Phase 2 APEC Study (2017) (17)
Performance of serum lipocalin 2 as a diagnostic marker for colorectal cancer. (2013) (17)
Fingers: three-dimensional MR imaging and angiography with a local gradient coil. (1994) (17)
Serum concentrations of brain-derived neurotrophic factor (BDNF) are decreased in colorectal cancer patients. (2013) (16)
Examining the impact of regular aspirin use and PIK3CA mutations on survival in stage 2 colon cancer (2017) (16)
AI-enhanced simultaneous multiparametric 18F-FDG PET/MRI for accurate breast cancer diagnosis (2021) (16)
Impact of Diabetes Status and Medication on Presentation, Treatment, and Outcome of Stage II Colon Cancer Patients (2015) (16)
A phase I/II trial of combined BRAF and EGFR inhibition in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal (mCRC): The EViCT (Erlotinib and Vemurafenib in Combination Trial) study. (2017) (16)
Tumour infiltrating lymphocyte status is superior to histological grade, DNA mismatch repair and BRAF mutation for prognosis of colorectal adenocarcinomas with mucinous differentiation (2020) (15)
Bilateral open breast coil and compatible intervention device (2000) (15)
Current opinion on optimal systemic treatment for metastatic colorectal cancer: outcome of the ACTG/AGITG expert meeting ECCO 2013 (2014) (15)
The potential role of circulating tumor DNA (ctDNA) in the further investigation of colorectal cancer patients with nonspecific findings on standard investigations (2019) (15)
Successful Treatment of Mucosa-Associated Lymphoid Tissue Lymphoma of the Rectum with Radiation Therapy: Report of a Case (2008) (15)
Patterns of care for metastatic renal cell carcinoma in Australia (2015) (15)
Radiomics and Machine Learning with Multiparametric Breast MRI for Improved Diagnostic Accuracy in Breast Cancer Diagnosis (2021) (15)
Medical management of cutaneous malignancies. (2001) (15)
Medically actionable pathogenic variants in a population of 13,131 healthy elderly individuals (2020) (14)
MRI radiomics features of mesorectal fat can predict response to neoadjuvant chemoradiation therapy and tumor recurrence in patients with locally advanced rectal cancer (2021) (14)
Lymph node yield following colorectal cancer surgery (2011) (14)
A Phase II Study of Irofulven (MGI 114) in Patients with Stage IV Melanoma (2002) (14)
Benefit from cytoreductive nephrectomy and the prognostic role of neutrophil‐to‐lymphocyte ratio in patients with metastatic renal cell carcinoma (2016) (14)
Mismatch repair deficiency assessment by immunohistochemistry: for Lynch syndrome screening and beyond. (2018) (14)
Survival, mortality and morbidity outcomes after oesophagogastric cancer surgery in New South Wales, 2001–2008 (2014) (14)
Comparison of 3.0 T magnetic resonance imaging and X-ray mammography in the measurement of ductal carcinoma in situ: a comparison with histopathology. (2015) (14)
The prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab: A translational study [ASCENT] (2018) (14)
Potential role of circulating tumor DNA (ctDNA) in the early diagnosis and post-operative management of localised pancreatic cancer. (2017) (14)
The Value of Clinical Colorectal Cancer Registries in Colorectal Cancer Research: A Systematic Review (2018) (14)
Snapshot echo-planar imaging methods: current trends and future perspectives (1990) (14)
Serial circulating tumor DNA (ctDNA) and recurrence risk in patients (pts) with resectable colorectal liver metastasis (CLM). (2016) (13)
The potential of circulating tumor DNA (ctDNA) to guide adjuvant chemotherapy decision making in locally advanced rectal cancer (LARC). (2017) (12)
PREOPERATIVE CHEMOTHERAPY AND RADIOTHERAPY FOR LOCALLY ADVANCED RECTAL CANCER (2005) (12)
Pre-Therapeutic Total Lesion Glycolysis on [18F]FDG-PET Enables Prognostication of 2-Year Progression-Free Survival in MALT Lymphoma Patients Treated with CD20-Antibody-Based Immunotherapy (2019) (12)
Subsite-Specific Colorectal Cancer in Diabetic and Nondiabetic Patients (2005) (12)
Chemotherapy treatments for metastatic colorectal cancer: is evidence-based medicine in practice? (2008) (12)
Germline Variants and Advanced Colorectal Adenomas: Adenoma Prevention with Celecoxib Trial Genome-wide Association Study (2013) (12)
Right versus left sided metastatic colorectal cancer: Teasing out clinicopathologic drivers of disparity in survival (2019) (12)
Emerging biomarkers for immunomodulatory cancer treatment of upper gastrointestinal, pancreatic and hepatic cancers. (2017) (12)
Impact of Surgical Complications Following Resection of Locally Advanced Rectal Adenocarcinoma on Adjuvant Chemotherapy Delivery and Survival Outcomes (2016) (11)
The Molecular Medicine Informatics Model (MMIM) (2007) (11)
Serious hepatic complications of selective internal radiation therapy with yttrium‐90 microsphere radioembolization for unresectable liver tumors (2014) (11)
Inflammation, Biomarkers and Immuno-Oncology Pathways in Pancreatic Cancer (2019) (11)
A novel magnetic bead‐based assay with high sensitivity and selectivity for analysis of telomerase in exfoliated cells from patients with bladder and colon cancer (2007) (11)
Spontaneous T cell responses to melanoma differentiation antigens from melanoma patients and healthy subjects (1998) (10)
A phase I trial of imatinib in combination with mFOLFOX6–bevacizumab in patients with advanced colorectal cancer (2013) (10)
Chemotherapy and biologic use in the routine management of metastatic colorectal cancer in Australia: is clinical practice following the evidence? (2019) (10)
Circulating tumor DNA as a biomarker to guide therapy in post-operative locally advanced rectal cancer: the best option? (2018) (10)
REsect: Blinded assessment of amenability to potentially curative treatment of previously unresectable colorectal cancer liver metastases (CRC LM) after chemotherapy ± RadioEmbolization (SIRT) in the randomized SIRFLOX trial. (2017) (10)
An initial watch and wait approach is a valid strategy for selected patients with newly diagnosed metastatic colorectal cancer. (2012) (10)
Circulating Tumour DNA as a Potential Cost-Effective Biomarker to Reduce Adjuvant Chemotherapy Overtreatment in Stage II Colorectal Cancer (2021) (10)
Circulating tumor DNA (ctDNA) in nonmetastatic colorectal cancer (CRC): Potential role as a screening tool. (2015) (10)
Metastasectomy and BRAF mutation; an analysis of survival outcome in metastatic colorectal cancer. (2020) (9)
Genomic Risk Score for Melanoma in a Prospective Study of Older Individuals. (2021) (9)
Effects of oncostatin M and tamoxifen on human melanoma cells (1998) (9)
Immunomodulation by MYB is associated with tumor relapse in patients with early stage colorectal cancer (2016) (9)
Systemic Inflammation - Impact on Tumor Biology and Outcomes in Colorectal Cancer (2015) (9)
Primary Tumor Resection and Overall Survival in Patients With Metastatic Colorectal Cancer Treated With Palliative Intent. (2016) (9)
Subgroup analysis of the ASPirin in Reducing Events in the Elderly randomized clinical trial suggest aspirin did not improve outcomes in older adults with chronic kidney disease. (2020) (9)
Sequencing Circulating Cell-Free DNA: The Potential to Refine Precision Cancer Medicine. (2016) (9)
Radiomics of high-resolution computed tomography for the differentiation between cholesteatoma and middle ear inflammation: effects of post-reconstruction methods in a dual-center study (2020) (9)
Assessment of the pore geometry of stereolithographic models by high resolution MRI. (1998) (8)
The influence of language spoken on colorectal cancer diagnosis and management (2006) (8)
CT-based Radiogenomic Analysis of Clinical Stage I Lung Adenocarcinoma with Histopathologic Features and Oncologic Outcomes. (2022) (8)
Survival Impact of Adjuvant Chemotherapy for Resected Locally Advanced Rectal Adenocarcinoma (2017) (8)
Accuracy of administrative coding data in colorectal cancer resections and short‐term outcomes (2018) (8)
Defining the susceptibility of colorectal cancers to BH3-mimetic compounds (2020) (8)
Pharmaco‐economic analysis of direct medical costs of metastatic colorectal cancer therapy with XELOX or modified FOLFOX‐6 regimens: Implications for health‐care utilization in Australia (2013) (8)
MAGE-12 and MAGE-6 are frequently expressed in malignant melanoma. (2000) (8)
The potential of circulating tumor DNA (ctDNA) to reshape the design of clinical trials testing adjuvant therapy in patients with early stage cancers. (2016) (8)
Novel quality indicators for metastatic colorectal cancer management identify significant variations in these measures across treatment centers in Australia (2015) (8)
Overexpression of TP53 protein is associated with the lack of adjuvant chemotherapy benefit in patients with stage III colorectal cancer (2019) (8)
Treatment with unfunded drugs in oncology: the impact of access programmes and clinical trials (2013) (8)
Low-viscosity matrix suspension culture enables scalable analysis of patient-derived organoids and tumoroids from the large intestine (2021) (7)
Translation of clinical trial outcomes to metastatic colorectal cancer patients in community practice (2014) (7)
Previous Bevacizumab and Efficacy of Later Anti–Epidermal Growth Factor Receptor Antibodies in Metastatic Colorectal Cancer: Results From a Large International Registry (2018) (7)
Impact of body mass index on colorectal cancer treatment and outcomes: need for prospective and comprehensive data. (2009) (7)
CD8+ tumor‐infiltrating lymphocytes within the primary tumor of patients with synchronous de novo metastatic colorectal carcinoma do not track with survival (2020) (7)
Tumor burden (TB) as a prognostic indicator in patients with metastatic colorectal cancer (mCRC). (2014) (7)
Clinical Applications of Circulating Tumour DNA in Pancreatic Adenocarcinoma (2019) (7)
The impact of bevacizumab in metastatic colorectal cancer with an intact primary tumor: Results from a large prospective cohort study (2017) (7)
Health Economic Models for Metastatic Colorectal Cancer: A Methodological Review (2020) (7)
A Phase II Study of Biochemotherapy for Advanced Melanoma Incorporating Temozolomide, Decrescendo Interleukin-2 and GM-CSF (2005) (7)
How safe is adjuvant chemotherapy and radiotherapy for rectal cancer? (2004) (7)
Breast Lesion Classification with Multiparametric Breast MRI Using Radiomics and Machine Learning: A Comparison with Radiologists’ Performance (2022) (6)
Multiparametric 18F-FDG PET/MRI-Based Radiomics for Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer (2022) (6)
Single‐institution experience of adjuvant 5‐fluorouracil‐based chemotherapy for stage III colon cancer (2008) (6)
FOXFIRE-SIRFLOX-FOXFIRE global prospective randomised studies of first-line selective internal radiotherapy (SIRT) in patients with liver metastases from colorectal cancer: KRAS mutation and tumour site analysis (2017) (6)
The influence of hypomagnesemia (hMg) on overall survival (OS) in a phase III randomized study of cetuximab (CET) plus best supportive care (BSC) versus BSC: NCIC CTG/AGITG CO.17. (2011) (6)
Making sense of uncertainty: why uncertainty is part of science (2013) (6)
Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015 (2016) (6)
Surveillance following treatment for colorectal cancer in Australia. Has best practice been adopted by medical oncologists? (2008) (6)
Quality of life in the FOXFIRE, SIRFLOX and FOXFIRE‐global randomised trials of selective internal radiotherapy for metastatic colorectal cancer (2019) (6)
Localization of MR-detected breast cancer using a prototype stereotactic guidance MR system (1997) (6)
Registry‐based randomized clinical trials as a method to improve cancer care in Australia (2019) (6)
Adjuvant chemotherapy use among older patients with stage III colon cancer. (2010) (6)
CLINICALLY USEFUL CALCULATIONS TOF THE DOSE DISTRIBUTION FROM MULTIPLE RADIATION SOURCES. (1965) (6)
CT Radiomic Features for Predicting Resectability and TNM Staging in Thymic Epithelial Tumors. (2021) (6)
Adjuvant therapy for resected colon cancer 2017, including the IDEA analysis (2018) (6)
Patient comorbidities and behaviour once diagnosed are major contributors to disparities in cancer health outcomes. (2010) (6)
Practical issues in adjuvant therapy for rectal cancer. (2003) (6)
The clinical potential of ultra-high-speed echo-planar imaging (1990) (5)
Surgical oncology issues in locally advanced rectal cancer (2011) (5)
A PHASE II TRIAL OF RADIOEMBOLIZATION AND SYSTEMIC CHEMOTHERAPY IN PATIENTS WITH LIVER METASTASES FROM PRIMARY CANCER OF THE PANCREAS (2010) (5)
OPTIMIZING THE APPROACH TO PATIENTS WITH POTENTIALLY RESECTABLE LIVER METASTASES FROM COLORECTAL CANCER (2007) (5)
Cancer history and risk factors in healthy older people enrolling in the ASPREE clinical trial. (2020) (5)
Clinical experience of selective internal radiation therapy in combination with systemic chemotherapy as first-line therapy in patients with unresectable hepatic metastases from colorectal cancer (2008) (5)
318MO Circulating tumour DNA (ctDNA) dynamics, CEA and sites of recurrence for the randomised DYNAMIC study: Adjuvant chemotherapy (ACT) guided by ctDNA analysis in stage II colon cancer (CC) (2022) (5)
Vandetanib with mFOLFOX6 in advanced colorectal adenocarcinoma: An open-label, multicenter phase I study (2007) (5)
Epidermal growth factor receptor ligands: targets for optimizing treatment of metastatic colorectal cancer. (2019) (5)
Results of a phase III, randomized, double-blind, placebo-controlled trial of pegfilgrastim (PEG) in patients (pts) receiving first-line FOLFOX or FOLFIRI and bevacizumab (B) for colorectal cancer (CRC). (2013) (5)
Assessing PD-L1 Expression Status Using Radiomic Features from Contrast-Enhanced Breast MRI in Breast Cancer Patients: Initial Results (2021) (5)
Treatment outcomes for patients with metastatic castrate‐resistant prostate cancer following docetaxel for hormone‐sensitive disease (2020) (5)
Evaluation of emergent circulating tumor (ct) DNA RAS mutations in patients with metastatic colorectal cancer (mCRC) treated with panitumumab (pmab) monotherapy from the ASPECCT study (2016) (5)
A critical review of the Glasgow Prognostic Score for colorectal cancer. (2008) (5)
Differences in sites of metastatic disease and outcomes observed in patients with BRAF mutant colorectal cancers. (2010) (5)
Background Parenchymal Enhancement on Breast MRI as a Prognostic Surrogate: Correlation With Breast Cancer Oncotype Dx Score (2021) (5)
Resection of colorectal cancer liver metastases in older patients (2020) (5)
Circulating tumor DNA as a prognostic biomarker in early stage pancreatic cancer. (2018) (5)
Phase II APEC trial: The impact of primary tumor side on outcomes of first‐line cetuximab plus FOLFOX or FOLFIRI in patients with RAS wild‐type metastatic colorectal cancer (2019) (5)
Evidence supports adjuvant radiotherapy in selected patients with rectal cancer (2004) (5)
Baseline Characteristics of Participants in the ASPREE (Aspirin in Reducing Events in the Elderly) Study. (2019) (5)
Diagnostic value of radiomics and machine learning with dynamic contrast-enhanced magnetic resonance imaging for patients with atypical ductal hyperplasia in predicting malignant upgrade (2021) (5)
The Diverse Applications of Pancreatic Ductal Adenocarcinoma Organoids (2021) (5)
Regular aspirin (ASA) use and survival in patients with PIK3CA-mutated metastatic colorectal cancer (CRC). (2014) (5)
50 Localized subcutaneous soft tissue sarcoma: Implications for the use of adjuvant radiation therapy (1995) (5)
Gastrointestinal perforation in metastatic colorectal cancer patients with peritoneal metastases receiving bevacizumab. (2015) (5)
Systematic Review of Efficacy and Health Economic Implications of Real-world Treatment Sequencing in Prostate Cancer: Where Do the Newer Agents Enzalutamide and Abiraterone Fit in? (2020) (5)
The outcome of patients (pts) with metastatic colorectal cancer (mCRC) based on site of metastases (mets) and the impact of molecular markers and site of primary cancer on metastatic pattern. (2017) (5)
Real-world incidence of symptomatic skeletal events and bone-modifying agent use in castration-resistant prostate cancer - an Australian multi-centre observational study. (2021) (5)
Impact of ComBat Harmonization on PET Radiomics-Based Tissue Classification: A Dual-Center PET/MRI and PET/CT Study (2022) (5)
Corrigendum: Baseline characteristics of participants in the ASPREE (Aspirin in Reducing Events in the Elderly) Study (Journals of Gerontology - Series A Biological Sciences and Medical Sciences DOI: 10.1093/gerona/glw342) (2019) (4)
Clinical outcomes and emergent circulating tumor (ct)DNA RAS mutations and allele fraction for patients with metastatic colorectal cancer (mCRC) treated with panitumumab from the ASPECCT study. (2017) (4)
Selecting subjects for a therapeutic target in colorectal cancer (CRC): Using a clinical database to enrich for patients harboring the BRAFV600E mutation. (2009) (4)
Impact of primary tumour location on survival in patients with metastatic colorectal cancer receiving selective internal radiation therapy and chemotherapy as first-line therapy. (2017) (4)
Hypertension as a predictor of advanced colorectal cancer outcome and cetuximab treatment response. (2018) (4)
Improved peripheral MR angiography with temperature regulation in healthy patients. (1996) (4)
Real‐world impact of anti‐HER2 therapy‐related cardiotoxicity in patients with advanced HER2‐positive breast cancer (2020) (4)
Re: Residual treatment disparities after oncology referral for rectal cancer. (2008) (4)
A Polygenic Risk Score Predicts Incident Prostate Cancer Risk in Older Men but Does Not Select for Clinically Significant Disease (2021) (4)
Impact of access to novel therapies on the initial management of castrate‐resistant prostate cancer: an Australian multicentre study (2019) (4)
Aspirin and the risk of colorectal cancer according to genetic susceptibility among older individuals. (2022) (4)
Analysis of 32 Blood-Based Protein Biomarkers for their Potential to Diagnose Colorectal Cancer (2015) (4)
Neoadjuvant Chemoradiotherapy and Tumor Recurrence in Patients with Early T-Stage Cancer of the Lower Rectum (2019) (4)
Re: Completion of therapy by Medicare patients with stage III colon cancer. (2006) (4)
Drinking from the firehose - A clinician's perspective on the challenges of delivering biomarker-driven care in routine practice. (2021) (4)
Evaluation of the use of computed tomography versus conventional orthogonal X-ray simulation in the treatment of rectal cancer. (2005) (4)
Risk-adjusted pathologic margin positivity rate: a problematic quality indicator. (2015) (4)
A direct comparison of cytolytic T-lymphocyte responses to Melan-A peptides in vitro: differential immunogenicity of Melan-A27-35 and Melan-A26-35. (2000) (4)
LBA-006Impact of primary tumour location on survival in patients with metastatic colorectal cancer receiving selective internal radiation therapy and chemotherapy as first-line therapy. (2017) (4)
Cancer clinical trial vs real‐world outcomes for standard of care first‐line treatment in the advanced disease setting (2021) (3)
Patterns of care of elderly patients with metastatic colorectal cancer. (2013) (3)
Circulating Tumour DNA to Guide Treatment of Gastrointestinal Malignancies (2020) (3)
Microsatellite instability status is critical to analysis of survival in stage II colon cancer. (2012) (3)
APER rate has multiple limitations as an indicator of quality in rectal cancer surgery. (2008) (3)
Outcomes in the surgical treatment of low rectal cancer: does neoadjuvant treatment equalize results? (2015) (3)
Personalizing First-Line Systemic Therapy in Metastatic Colorectal Cancer: Is There a Role for Initial Low-Intensity Therapy in 2021 and Beyond? A Perspective From Members of the Australasian Gastrointestinal Trials Group. (2021) (3)
Texture analysis of 3T high resolution T2 weighted images in ovarian cystadenoma versus borderline tumour (2013) (3)
Appendiceal neoplasm incidence and mortality rates are on the rise in Australia (2020) (3)
Stage dependent recurrence patterns and post-recurrence outcomes in non-metastatic colon cancer (2021) (3)
Precision oncology using a clinician‐directed, tailored approach to molecular profiling (2018) (3)
Simulating Progression-Free and Overall Survival for First-Line Doublet Chemotherapy With or Without Bevacizumab in Metastatic Colorectal Cancer Patients Based on Real-World Registry Data (2020) (3)
The tumor immune microenvironment differs between metastatic castrate resistant prostate cancer (CRPC) and hormone sensitive prostate cancer (HSPC). (2019) (3)
Genomic Risk Prediction for Breast Cancer in Older Women (2021) (3)
Left- versus right-side metastatic colorectal cancer: Teasing out clinicopathologic drivers of disparity in survival. (2019) (3)
BRAF, PIK3CA, and PTEN status and benefit from cetuximab (CET) in the treatment of advanced colorectal cancer (CRC): Results from NCIC CTG/AGITG CO.17. (2012) (3)
Emerging strategies in the initial management of locally advanced rectal cancer. (2019) (3)
Thrombocytopenia: New approaches to resolve a major problem in chemotherapy (1995) (3)
Evaluation of the transferability of survival calculators for stage II/III colon cancer across healthcare systems (2019) (3)
Can systemic inflammation at diagnosis predict benefit from primary resection in metastatic colorectal cancer (mCRC) (2013) (3)
Comment on: Completion of therapy by medicare patients with stage III colon cancer (2006) (2)
Is there a role for chemotherapy in metastatic colorectal cancer patients with a poor performance status (2013) (2)
Quality of life in patients with liver metastases from colorectal cancer treated with first-line selective internal radiotherapy (SIRT): Results from the FOXFIRE prospective randomized studies (2017) (2)
Overall survival analysis of the FOXFIRE-SIRFLOX-FOXFIRE global prospective randomized studies of first-line selective internal radiotherapy (SIRT) in patients with liver metastases from colorectal cancer. (2017) (2)
An Australian translational Study to evaluate the prognostic role of inflammatory markers in patients with metastatic ColorEctal caNcer Treated with bevacizumab (Avastin™) [ASCENT] (2013) (2)
Understanding why some people with stage III colon cancer do not receive adjuvant chemotherapy. (2013) (2)
Patient demographics and management landscape of metastatic colorectal cancer in the third-line setting: Real-world data in an Australian population (2019) (2)
Hemolysis and thrombocytopenia following oxaliplatin administration (2005) (2)
BRAFV600E Mutations Arising from a Left-Side Primary in Metastatic Colorectal Cancer: Are They a Distinct Subset? (2021) (2)
RE: Aspirin and COX-2 Inhibitor Use in Patients With Stage III Colon Cancer. (2015) (2)
Use and outcomes of chemotherapy for metastatic pancreatic cancer in Australia (2020) (2)
Impact of primary tumor side (TS) on outcomes of once-every-2-weeks (q2w) cetuximab + first-line (1L) FOLFOX or FOLFIRI in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 2 APEC trial. (2018) (2)
Does adjuvant chemotherapy in elderly patients with stage III colon cancer really save lives? (2013) (2)
Intratumorous heterogeneity for RAS mutations in a treatment-naïve colorectal tumour (2017) (2)
A New Strategy for Consistent Uniform Fat Suppression in Breast MR Imaging (2011) (2)
Financial incentives in cancer care and impact on prescribing practice. (2013) (2)
Metastatic colorectal cancer (mCRC) with primary in situ: An Australian registry. (2013) (2)
Guesstimates are not good enough for determining what is happening in routine care (2010) (2)
Treatment outcomes for metastatic castrate-resistant prostate cancer (mCRPC) patients (pts) following docetaxel (D) for hormone sensitive disease. (2020) (2)
Real-world survival outcomes of using neoadjuvant chemotherapy in pancreatic cancer patients: Findings from the PURPLE clinical registry. (2020) (2)
Trifluridine/tipiracil: A practical guide to its use in the management of refractory metastatic colorectal cancer in Australia (2020) (2)
The effect of smoking, obesity and diabetes on recurrence‐free and overall survival in patients with stage III colon cancer receiving adjuvant chemotherapy (2021) (2)
Metastatic colorectal cancer and management in public versus private hospitals: Similarities and differences. (2013) (2)
Type 2 Diabetes Mellitus, Smoking, and Colorectal Cancer (2007) (2)
Beyond cabazitaxel: Late line treatments in metastatic castration resistant prostate cancer: A retrospective multicentre analysis (2019) (2)
The Molecular Medicine Informatics Model (MMIM). (2007) (2)
Incidence of pulmonary embolism in patients with newly diagnosed colorectal cancer (2018) (2)
Real‐world first‐line systemic therapy patterns in metastatic castration‐resistant prostate cancer (2021) (2)
EFFECT OF INITIATING ASPIRIN ON CANCER EVENTS IN THE HEALTHY ELDERLY (2019) (2)
Determinants of lymph node yield in colorectal cancer: Analysis of 9,867 patients from prospective Australian databases (2008) (2)
Massively parallel sequencing (MPS) of circulating DNA in patients with metastatic colorectal cancer (mCRC): Prognostic significance and early changes during chemotherapy (CT). (2013) (2)
Analysis of colorectal cancers in British Bangladeshi identifies early onset, frequent mucinous histotype and a high prevalence of RBFOX1 deletion (2013) (2)
The development of hyaluronic acid as a targeted transport vehicle for chemotherapeutic drugs (2005) (2)
A pooled analysis of multicenter cohort studies of post-surgery circulating tumor DNA (ctDNA) in early stage colorectal cancer (CRC). (2019) (2)
Clinical registries data quality attributes to support registry-based randomised controlled trials: A scoping review. (2022) (2)
Second primary colorectal cancer in the era of prevalent screening and imaging (2013) (2)
Profiling circulating tumor (ct)DNA mutations after panitumumab treatment in patients with refractory metastatic colorectal cancer (mCRC) from the phase III ASPECCT study. (2017) (2)
Demonstrating the feasibility of collecting secondary, de‐identified data on Australian patients receiving treatment as part of a Medicine Access Programme (2020) (2)
Radiogenomics in personalized management of lung cancer patients: Where are we? (2022) (2)
Lynch syndrome testing of colorectal cancer patients in a high-income country with universal healthcare: a retrospective study of current practice and gaps in seven australian hospitals (2022) (2)
Prediction of disability-free survival in healthy older people (2022) (2)
Radioembolization for colorectal cancer liver metastases: current role and future opportunities - the medical oncologist's perspective (2014) (1)
3052 POSTER Impact of diabetes mellitus on the development and outcomes of colorectal cancer (2007) (1)
Safety and efficacy of bevacizumab and systemic therapy in metastatic colorectal cancer (mCRC) patients with peritoneal disease in the Treatment of Recurrent and Advanced Colorectal Cancer (TRACC) database. (2014) (1)
Metastasectomy and BRAF mutation: An analysis of survival outcome in metastatic colorectal cancer. (2019) (1)
Abstract IA17: Non-invasive detection of somatic mutations in the management of CRC (2017) (1)
S280 Incident Cancer Risk and Mutation Signatures Among Elderly MUTYH Carriers: Analysis of Population-Based and Genomic Cohorts (2021) (1)
Prognostic immunoprofiling of muscle invasive bladder cancer (MIBC) patients in a multicentre setting (2019) (1)
Impact of tumor site on bevacizumab (BEV) efficacy in metastatic colorectal cancer (mCRC). (2014) (1)
Adequate SIRT activity dose is as important as adequate chemotherapy dose - Authors' reply. (2017) (1)
226P Use of PSMA PET in metastatic castration-resistant prostate cancer (mCRPC) (2020) (1)
Cancer classification using the Immunoscore: a worldwide task force (2012) (1)
Initial experience of TAS-102 chemotherapy in Australian patients with chemorefractory metastatic colorectal cancer. (2021) (1)
Treatment sequencing and outcomes in synchronous metastatic rectal cancer. (2017) (1)
Impact of anti-VEGF therapy in metastatic colorectal cancer with an intact primary tumour. (2016) (1)
First-line clinical trials and metastatic colorectal cancer: How selected are clinical trial participants? (2013) (1)
Aspirin use and survival outcomes in patients (pts) with PIK3CA mutant colorectal cancer (CRC). (2013) (1)
Problematic Use of Multiple Subgroup Analyses in Assessing the Impact of Aspirin in Prostate Cancer. (2015) (1)
Gastrointestinal tumors, colorectal (2012) (1)
Real-World Treatment and Outcomes of Metastatic Colorectal Cancer Patients With a Poor or Very Poor Performance Status. (2020) (1)
Using a prospective comprehensive database to define features that impact the outcome of patients with glioblastoma multiforme. (2010) (1)
Abstract 4920: Evaluation of a diagnostic blood test for colorectal cancer screening and as a triage tool to stratify patients for colonoscopy (2016) (1)
Real-World Outcomes of Ribociclib and Aromatase Inhibitor Use in First Line Hormone Receptor Positive, HER2-Negative Metastatic Breast Cancer. (2022) (1)
Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: the SIRFLOX study (2014) (1)
Fractured malar. (1985) (1)
Radioembolization for hepatocellular carcinoma: current role and future directions - the medical oncologist's perspective. (2015) (1)
Positive lateral pelvic lymph nodes in low rectal cancer: should we change our practice now? (2021) (1)
An incorrect diagnosis of metastatic colorectal cancer: The need for tissue diagnosis prior to treatment (2007) (1)
SIRFLOX: Differences in site of first progression between mFOLFOX6 ± bevacizumab (bev) versus mFOLFOX6 ± bev + selective internal radiation therapy (SIRT) in first-line patients (pts) with metastatic colorectal cancer (mCRC) (2016) (1)
The role of tissue diagnosis prior to neoadjuvant chemoradiotherapy for locally advanced rectal cancer (2014) (1)
Investigating real-world treatment sequencing outcomes in advanced pancreatic cancer: A purple translational registry analysis. (2021) (1)
Beyond standard data collection – the promise and potential of BRAIN (Brain tumour Registry Australia INnovation and translation registry) (2022) (1)
Chemotherapy in older adults with colorectal cancer (2013) (1)
Leveraging Comprehensive Cancer Registry Data to Enable a Broad Range of Research, Audit and Patient Support Activities (2022) (1)
Abstract 4138: miRNA-362-3p is associated with recurrence of colorectal cancer and targets E2F1, USF2 and PTPN1 (2012) (1)
Genotype-Tailored ERK/MAPK Pathway and HDAC Inhibition Rewires the Apoptotic Rheostat to Trigger Colorectal Cancer Cell Death (2022) (1)
REsect: blinded assessment of resectability of previously unresectable colorectal cancer liver metastases following chemotherapy±Y90-RadioEmbolization (2019) (1)
O-8 Final overall survival for the phase 3 KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer (2021) (1)
Utilisation of systemic therapy options in routine treatment of metastatic colorectal cancer in Australia (2020) (1)
Impact of prior (neo)adjuvant trastuzumab (NAT) exposure on the efficacy of HER2-targeted therapy for metastatic breast cancer (2020) (1)
Resilience to dominant genetic disease in the healthy elderly (2019) (1)
Feasibility of contrast-enhanced MRI derived textural features to predict overall survival in locally advanced breast cancer (2019) (1)
Circulating Levels of the Wnt Antagonist Dkk-3 as a Diagnostic Markerfor Colorectal Cancer (2012) (1)
Prescribing patterns for bevacizumab in first-line metastatic colorectal cancer: Exploring the introduction of a new drug into routine clinical practice. (2012) (1)
Onco-microbial community profiling identifies clinico-molecular and prognostic subtypes of colorectal cancer. (2023) (1)
Pertuzumab study in the neoadjuvant setting for HER2‐positive nonmetastatic breast cancer in Australia (PeRSIA) (2022) (1)
Left versus right sided colorectal cancer: Teasing out drivers of disparity in outcomes in metastatic disease. (2017) (1)
Impact of primary tumor stage on survival following resection of metachronous liver and/or lung metastases in colorectal cancer. (2015) (1)
Effect of DNA-PK dependent phosphorylation of topo-I-S10 on its rate of proteasomal degradation and CPT response. (2015) (1)
Patterns of care according to treatment intent for metastatic colorectal cancer (mCRC): A two-year review of routine practice. (2012) (1)
Addition of endocrine therapy to dual anti-HER2 targeted therapy in initial treatment of HER2 + /HR + metastatic breast cancer (2020) (1)
Is Universal Next-Generation Sequencing Testing of Patients With Advanced Cancer Ready for Prime Time? (2021) (1)
Real‐world outcomes for neoadjuvant capecitabine versus infusional 5‐fluorouracil in the treatment of locally advanced rectal cancer (2020) (1)
A Highly Sensitive Immunohistochemical Assay to Detect Braf V600E Mutations in Patients with Colorectal Cancer (2012) (1)
Using data from the SIRFLOX study to evaluate depth of response within a volumetric model in patients with metastatic colorectal cancer (2017) (1)
Compliance with TGA prescribing information - Weekly or second weekly cetuximab for the treatment of metastatic colorectal cancer. (2022) (1)
Patient demographics and management landscape of metastatic colorectal cancer in the third‐line setting: Real‐world data in an australian population (2021) (1)
Delivery and effectiveness of adjuvant therapy for stage III colon cancer in routine clinical practice. (2014) (1)
Impact of first-line bevacizumab therapy on the efficacy of subsequent anti-epidermal growth factor antibodies (anti-EGFR) in metastatic colorectal cancer (mCRC). (2016) (1)
Chemotherapy (CT) dose adjustment for obese or elderly patients: How often does it occur, and should it? Results of an Australian survey (2007) (1)
Imaging , Diagnosis , Prognosis PIK 3 CA and PTEN Gene and Exon Mutation-Speci fi c Clinicopathologic and Molecular Associations in Colorectal Cancer (2013) (1)
A direct comparison of cytolytic T‐lymphocyte responses to Melan‐A peptides in vitro: differential immunogenicity of Melan‐A27‐35 and Melan‐A26‐35 (2000) (1)
Multicohort Retrospective Validation of a Predictive Biomarker for Topoisomerase I Inhibitors. (2020) (1)
Phase II trial of selective internal radiation therapy and systemic chemotherapy for liver-predominant metastases from pancreatic adenocarcinoma (2015) (1)
Can Follow-up be Avoided for Probably Benign US Masses with No Enhancement on MRI? (2020) (1)
Impact of adjuvant chemotherapy and patient age on patterns of metastatic recurrence in stage III colorectal cancer. (2021) (1)
400a – Effect of Initiating Aspirin on Cancer Events in the Healthy Elderly: Primary Results from the Aspree Randomized Controlled Trial (2019) (1)
The value of real time adjustment of T1 weighting in ultra high speed IR-EPI of the brain (1991) (1)
Current colorectal cancer chemotherapy dosing limitations and novel assessments to personalize treatments (2022) (1)
O-019SIRFLOX: Randomized trial comparing first-line mFOLFOX6 ± bevacizumab versus mFOLFOX6 + selective internal radiation therapy (SIRT) ± bevacizumab in patients with metastatic colorectal cancer (mCRC) – analysis by presence or absence of extra-hepatic metastases and bevacizumab treatment (2015) (1)
Registration of Supine MR Mammography with Breast Ultrasound for Surgical Planning of Breast Conserving Surgery: A Feasibility Study (2015) (1)
Bridging health access disparities among culturally and linguistically diverse cancer patients: an ongoing challenge (2018) (0)
Ultrafast dynamic contrast-enhanced breast MRI may generate prognostic imaging markers of breast cancer (2020) (0)
CORRELATION OF MAGNETIC RESONANCE DIFFUSION MAGING WITH CELL DENSITY IN PROSTATE CANCER (2008) (0)
Optimistaion of b-value distribution in biexponential modelling (2011) (0)
Conventional and radiomic features to predict pathology in the preoperative assessment of anterior mediastinal masses. (2023) (0)
Assessment of Four Different DWI Pulse Sequences Used for Breast Imaging (2009) (0)
Textural Analysis Optimisation in MRI of the Breast (2005) (0)
Diffusion-weighted imaging at 3 T for response prediction to chemoradiotherapy in cervical cancer (2010) (0)
Textural Analysis of the Prostate using Co-occurence matrices (2001) (0)
Measuring water T 2 and water : fat signal ratios with MR spectroscopy ( TEA-PRESS ) and chemical shift imaging ( IDEAL ) : preliminary results in phantoms and breast cancer chemotherapy patients (2008) (0)
2D Analysis of FSE Prostate images using Principal Component Analysis Hybrid Neural Network (1997) (0)
Textural Analysis of DCE-MRI of the Breast as a Predictor of Response (2010) (0)
Feasibility of multi-layered perceptron network in discriminating breast magnetic resonance imaging lesions (2005) (0)
Associations with Disease Free Survival and Pre treatment Texture Features Obtained From Dynamic Contrast Enhanced Breast Images (2012) (0)
Correlation of ADC and T2 with cell density in prostate cancer at 3.0T (2008) (0)
A Simultaneous Multiparametric 18F-FDG PET/MRI Radiomics Model for the Diagnosis of Triple Negative Breast Cancer (2022) (0)
Quantitative evaluation of diffusion weighted imaging techniques for radiotherapy of prostate cancer (2013) (0)
The American Brachytherapy Society consensus statement for permanent implant brachytherapy using Yttrium-90 microsphere radioembolization for liver tumors. (2022) (0)
AI-enhanced Synchronized Multiparametric 18F-FDG PET/MRI for Accurate Breast Cancer Diagnosis (2021) (0)
Development of a T 2 Weighted 3 D CUBE Inversion Recovery Fat Nulled Sequence for Breast Imaging (2011) (0)
High resolution magnetic resonance imaging of the finger: clinical applications (1996) (0)
3D MRI and angiography of human extremities using a local gradient coil (1994) (0)
Associations of breast MR derived vascular , shape and texture parameters with histological prognostic indicators (2010) (0)
NMR Imaging: Current Status and Future Prospects (1990) (0)
FAST IMAGING AND SERIAL SCANNING (1994) (0)
Pharmacokinetic, shape and texture parameters: comparison with breast tumour grade (2006) (0)
ComBat Harmonization for MRI Radiomics: Impact on Nonbinary Tissue Classification by Machine Learning. (2023) (0)
P47.06 Delta-Radiomics Features for Assessment of Individualized Therapeutic Response in Small Cell Lung Cancer – A Pilot Study (2021) (0)
Quantification using Textural Analysis on MR Bone Data (2010) (0)
LONGTERM IMAGING OF THE GASTROINTESTINAL-TRACT USING ECHO PLANAR MAGNETIC-RESONANCE IMAGING (1989) (0)
Feasibility of Multi-LayeredPerceptron Network inDiscriminating BreastMagnetic Resonance ImagingLesions (2005) (0)
Uptake of bone‐modifying agents in patients with HER2+ metastatic breast cancer with bone metastases – prospective data from a multi‐site Australian registry (2021) (0)
T‐stage downstaging of locally advanced rectal cancer after neoadjuvant chemoradiotherapy is not associated with reduced recurrence after adjusting for tumour characteristics (2022) (0)
CR37P UNREVERSED STOMAS IN RECTAL CANCER (2009) (0)
Real-World Use of First-Generation Anti-androgens (FGAs): Their Influence on Patient Outcomes and Subsequent Therapies in Metastatic Castration-Resistant Prostate Cancer (mCPRC) (2019) (0)
THE MIA PRIZE OF THE SECTION OF SURGERY OF THE ROYAL SOCIETY OF MEDICINE O15 FOXO3A EXPRESSION IN COLORECTAL CANCER: A PROMISING BIOMARKER OF MICROMETASTASES (2012) (0)
Effect of Aspirin on Melanoma Incidence in Older Persons: Extended Follow-up of a Large Randomized Double-blind Placebo-controlled Trial. (2022) (0)
Primary tumor resection in metastatic colorectal cancer (mCRC): A prospective cohort study. (2013) (0)
Characteristics and outcomes of participants in colorectal cancer biomarker trials versus a real-world cohort (2020) (0)
Pembrolizumab in Asian patients with microsatellite‐instability‐high/mismatch‐repair‐deficient colorectal cancer (2022) (0)
569PGIV AS A NOVEL PROGNOSTIC MARKER IN STAGE II COLON CANCER. (2014) (0)
Inflammation, Biomarkers and Personalized Therapies in Pancreatic Cancer (2019) (0)
Biomarker panel discovery for early detection of colorectal cancer in blood samples (2010) (0)
Health economic analysis of doublet chemotherapy with and without bevacizumab for first-line treatment of RAS mutant metastatic colorectal cancer based on real-world data. (2020) (0)
PCN212 PERSONALIZED DISCRETE EVENT SIMULATION OF PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL FOR FIRST-LINE DOUBLET CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB IN METASTATIC COLORECTAL CANCER (2019) (0)
ASPREE Healthy Ageing Biobank (2010) (0)
Biology and Clinical Implications of Fecal Occult Blood Test Screen-Detected Colorectal Cancer (2022) (0)
Associations between Metformin and Aspirin Use on Cancer Incidence and Mortality in Older Adults. (2021) (0)
Underestimation of Risk by Gail Model Extends Beyond Women With Atypical Hyperplasia (2009) (0)
Fractured body of the mandible. (1985) (0)
Incident Cancer Risk and Signatures Among Older MUTYH Carriers: Analysis of Population-Based and Genomic Cohorts. (2022) (0)
Abstract P1-18-15: Pertuzumab study for HER2-positive non-metastatic breast cancer in the neoadjuvant setting in Australia: Interim analysis (2020) (0)
Treatment and Outcomes of Oligometastatic Colorectal Cancer Limited to Lymph Node Metastases. (2021) (0)
SIRFLOX study: Novel approach to define depth of response (DpR) within a volumetric model in patients with metastatic colorectal cancer (mCRC). (2016) (0)
Hypertension as a predictor of outcome and treatment response to cetuximab: A retrospective analysis of NCIC CTG CO.17. (2016) (0)
Australian real-world outcomes of ribociclib and aromatase inhibitor in hormone receptor (HR) positive, HER2 negative metastatic breast cancer (MBC): Results from Kisqali Access Registry for Metastatic breast cancer in Australia (KARMA) collected alongside a medicine access program. (2021) (0)
Circulating Tumor DNA as a Prognostic Marker in Stage III Colon Cancer-Reply. (2020) (0)
Adjuvant chemotherapy (AC) choices: An analysis of elderly Australian patients with stage III colorectal cancer (CRC). (2021) (0)
Impact of first-line FOLFIRINOX versus Gemcitabine/Nab-Paclitaxel chemotherapy on survival in advanced pancreatic cancer: Evidence from the prospective international multicentre PURPLE pancreatic cancer registry. (2022) (0)
P61 Cost Utility Analysis of Circulating Tumour DNA Guided Adjuvant Chemotherapy in Stage II Colon Cancer (2022) (0)
Cancer diagnosis, cancer treatment, and association with cardiovascular disease in older adults: Results from ASPREE. (2022) (0)
Prognostic impact of clinicopathologic features in metastatic rectal versus colon cancer. (2014) (0)
Long-Term Results of Autologous Hematopoietic Stem-Cell Transplantation After High-Dose (2013) (0)
Circulating Tumor DNA Guiding Adjuvant Therapy in Colon Cancer. Reply. (2022) (0)
P0183 Resection of colorectal cancer metastases in routine practice (2014) (0)
Survival impact of adjuvant chemotherapy for resected early-stage rectal adenocarcinoma. (2015) (0)
Impact of clinical and molecular features on risk of recurrence following curative intent resection of metastases in metastatic colorectal cancer. (2017) (0)
The possible role of insulin-like growth factors and matrix metalloproteinases as a diagnostic of colorectal cancer. (2006) (0)
Muscle invasive (MIBC) and metastatic (mBC) urothelial cancer: Modern treatment practices and clinical outcomes in Victoria (2019) (0)
Anticoagulation prophylaxis for central venous catheter‐associated thrombosis in cancer patients: An Australian perspective (2008) (0)
Patterns of surveillance for colorectal cancer: Experience from a single large tertiary institution (2020) (0)
Pretreatment diffusion-weighted imaging at 3 T for overall survival prediction in chemoradiotherapy treated advanced cervical cancer patients (2011) (0)
SIRFLOX: Differences in site of first progression between mFOLFOX6 +/- bevacizumab (bev) versus mFOLFOX6 +/- bev plus selective internal radiation therapy (SIRT) in first-line patients (pts) with metastatic colorectal cancer (mCRC). (2016) (0)
6110 Influence of smoking on the clinico-pathological features of colorectal cancer: review of a prospective database (2009) (0)
A phase I trial of imatinib (IM) plus mFOLFOX-bevacizumab in patients with advanced colorectal cancer. (2011) (0)
Immunohistochemical evaluation of the prognostic and predictive power of epidermal growth factor receptor ligand levels in patients with metastatic colorectal cancer (2020) (0)
Use of folfirinox chemotherapy in an Australasian population of pancreatic cancer. (2018) (0)
Use and impact of selective internal radiation therapy (SIRT) in routine care patients with metastatic colorectal cancer (mCRC). (2016) (0)
Predictive Biomarkers and Personalized Medicine PIK 3 CA , BRAF , andPTENStatus andBene fi t fromCetuximab in the Treatment of Advanced Colorectal Cancer — Results from NCIC CTG / AGITG CO . 17 (2014) (0)
Comparing survival outcomes for patients with colorectal cancer treated in public and private hospitals (2007) (0)
Real‐world staging computed tomography scanning technique and important reporting discrepancies in pancreatic ductal adenocarcinoma (2022) (0)
ON1 UNDERSTANDING VARIATION IN TREATMENT SEQUENCES AND OUTCOMES IN METASTATIC COLORECTAL CANCER: USING REAL WORLD DATA TO ANSWER REAL WORLD QUESTIONS (2019) (0)
Association between type 2 diabetes mellitus (T2DM), diabetic therapies and clinical outcomes in patients (pts) with metastatic colorectal cancer (mCRC). (2015) (0)
CR11 *THE MULTIDISCIPLINARY MEETING IN COLORECTAL CANCER SERVICE – ATTITUDES OF CLINICIANS AND THE IMPACT UPON PATIENT MANAGEMENT (2009) (0)
Diagnosis and Clinical Management of Skin Cancer (2000) (0)
Utilization of systemic therapy options in the routine treatment of metastatic colorectal cancer. (2017) (0)
Are the survival benefits associated with primary resection in de novo metastatic colorectal cancer (mCRC) mediated by reversal of systemic inflammation (2014) (0)
O7-3 Pembrolizumab vs chemotherapy in MSI-H / dMMR metastatic colorectal cancer: KEYNOTE-177 final analysis Asia subgroup (2022) (0)
Adjuvant chemotherapy for stage II and stage III colon cancer-What is happening in routine practice? (2009) (0)
Prostate‐specific membrane antigen positron emission tomography‐computed tomography use prior to systemic therapy in metastatic castration‐resistant prostate cancer (2023) (0)
Abstract IA05: ctDNA and MRD in colorectal cancer: Time to reinvent adjuvant clinical trials (2020) (0)
Resection of Colorectal Cancer Liver Metastases in the Older Patient (2020) (0)
160MO Concomitant medication (conmed) interactions with novel hormonal agents (NHAs) in metastatic castration resistant prostate cancer (mCRPC) (2022) (0)
Role of radiotherapy in solitary bone plasmacytomas (2005) (0)
Molecular classification of hormone‐sensitive and castration‐resistant prostate cancer, using nonnegative matrix factorization molecular subtyping of primary and metastatic specimens (2022) (0)
112P Pembrolizumab vs chemotherapy in patients with microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: Asia subgroup results of the phase III KEYNOTE-177 study (2020) (0)
Which side is better? The impact of primary tumor side in early stage colorectal cancer (CRC). (2017) (0)
EP08.04-002 Australian Vinorelbine Use in Advanced Lung cancer (The AVAL Study) (2022) (0)
Circulating Tumor DNA in Colorectal Cancer—From Concept to Clinic (2019) (0)
OP-IJEJ210168_5 181..182 ++ (2021) (0)
Use of Bone-Modifying Agents in Australian Men with Castration-Resistant Prostate Cancer (CRPC) (2018) (0)
Clinicopathological characteristics and outcomes of young patients (YP) with metastatic colorectal cancer (mCRC) in Australia. (2015) (0)
An analysis of colorectal cancer (CRC) following a diagnosis of prostate cancer (CaP): Is it due to earlier diagnosis or increased incidence? (2011) (0)
Abstract P2-13-38: Pertuzumab study for HER2-positive non-metastatic breast cancer in the neoadjuvant setting in Australia (2022) (0)
EE149 Predicting the Population Budget Impact of Current and New Listings for Colorectal Cancer: The PRIMCAT-CRC Model (2022) (0)
Beyond standard data collection – the promise and potential of BRAIN (Brain tumour Registry Australia INnovation and translation registry) (2022) (0)
Examining skeletal-related events in Australian men with castration-resistant prostate cancer (CRPC). (2018) (0)
Variable implementation of optimal therapeutic strategies in metastatic colorectal cancer: Reviewing rates of liver resection and triplet chemotherapy across Australian hospitals as potential quality indicators. (2021) (0)
Comment on Timing of Surgery For Patients With Rectal Cancers Not Responding to Preoperative Chemoradiation. (2022) (0)
51P Real world outcomes in elderly women with HER2-positive advanced breast cancer (2020) (0)
Early Death After Chemotherapy as a Quality Indicator-Is It Time to Bench the Benchmark? (2022) (0)
Reply to E.C. Harrold et al and A.O. Ayoola et al. (2016) (0)
Hypertension and beta-blocker use as prognostic and predictive factors in metastatic colorectal cancer: A retrospective analysis of NCIC CTG CO.17. (2016) (0)
Clinical and histological diagnosis of skin cancer. (1982) (0)
TGF-β1 induced S100 family protein expression is associated with epithelial to mesenchymal transition states and poor survival in pancreatic cancer (2022) (0)
Edinburgh Research Explorer Germline Variants and Advanced Colorectal Adenomas (2017) (0)
Real-world adjuvant chemotherapy treatment patterns and outcomes over time for resected stage II and III colorectal cancer. (2022) (0)
Clinical implications of assumptions in cost-effectiveness analyses of systemic therapies for metastatic colorectal cancer. (2020) (0)
PO-065 Assessment of prognostic models for stage II/III colon cancer: a hospital-based prospective cohort study (2018) (0)
Lynch syndrome testing of colorectal cancer patients in a high-income country with universal healthcare: a retrospective study of current practice and gaps in seven australian hospitals (2022) (0)
1319 Microsatellite instability in sporadic colorectal cancer: correlation with novel clinical parameters (2009) (0)
Impact of the evolution in RAS mutation analysis in Australian patients with metastatic colorectal cancer (2022) (0)
P-187 Epidermal growth factor receptor inhibitors (EGFRi) in patients with left-side, RAS wildtype metastatic colorectal cancer: Clinician use and outcomes for patients (2022) (0)
Australian contemporary management of synchronous metastatic colorectal cancer (2018) (0)
Immune profile and survival outcomes in stage 2 colon cancer. (2016) (0)
513PIMPACT OF TUMOUR SITE ON BEVACIZUMAB EFFICACY IN METASTATIC COLORECTAL CANCER (MCRC). (2014) (0)
PCN126 REAL-WORLD TREATMENT SEQUENCING OF ABIRATERONE AND ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC): WHAT ARE THE HEALTH ECONOMIC IMPLICATIONS? (2019) (0)
The effect of hyaluronic acid on the activity of intra-tumoral and intestinal β-Glucuronidases - a potential mechanism for increasing the therapeutic index of Irinotecan (2006) (0)
Cancer Treatment Patterns and Factors Affecting Receipt of Treatment in Older Adults: Results from the ASPREE Cancer Treatment Substudy (ACTS) (2022) (0)
Abstract A032: Circulating tumor (ct)DNA mutations inEGFRpathway genes and clinical outcomes for patients with metastatic colorectal cancer (mCRC) treated with panitumumab from the ASPECCT study (2018) (0)
Chemotherapy at the end of life in colorectal and pancreatic cancer: Real-world data and trends over time. (2021) (0)
Point-of-care capture of clinical interventions for metastatic colorectal cancer (mCRC) to develop and validate novel markers of the quality of cancer care. (2014) (0)
Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes (2023) (0)
PCN95 Pharmacoeconomic Analysis of Direct Medical Costs Associated With the Treatment of Advanced Esophago-Gastric Cancer Therapy With Xeloda or 5-Fluorouracil (5-FU) Regimens: Implications for Health Care Utilisation in Australia (2012) (0)
Association between hypertension and cutaneous melanoma, and the effect of aspirin: extended follow-up of a large randomised controlled trial. (2022) (0)
The development of tumor-activated hyaluronic acid chemotherapeutic drugs (2007) (0)
Real-world clinical outcomes and cost estimates of metastatic castration-resistant prostate cancer treatment: does sequencing of taxanes and androgen receptor-targeted agents matter? (2022) (0)
Use and impact of perioperative chemotherapy in patients with resectable colorectal cancer metastases. (2020) (0)
Diagnostic accuracy of diffusion weighted imaging in the prostate (2001) (0)
Escalated dose docetaxel (TXT) with G-CSF support in patients (PTS) with solid tumours (1999) (0)
EP16.03-005 Australian Non-Small Cell Lung Cancer (NSCLC) Biomarker Testing Practices - A Survey of Medical Oncologists and Pathologists (2022) (0)
8716 POSTER Novel Features That Impact the Outcome of Patients With Glioblastoma Multiforme – Multivariate Analysis From a Comprehensive Dataset (2011) (0)
Is increasing nodal count associated with improved recurrence‐free and overall survival following standard right hemicolectomy for colon cancer? (2022) (0)
Abstract B014: Genotype-tailored ERK/MAPK pathway and HDAC inhibition rewires the apoptotic rheostat to trigger colorectal cancer cell death (2022) (0)
3066 POSTER Exploring first line chemotherapy options in metastatic colorectal cancer (mCRC): nationwide heterogeneity in patient management (2007) (0)
Use and impact of bevacizumab in patients undergoing liver resection for metastatic colorectal cancer in routine clinical practice. (2016) (0)
Emerging trends in the prediction of pathological tumour response in rectal cancer following neoadjuvant therapy. (2023) (0)
Characteristics and outcomes for fecal occult blood test (FOBT) screen detected (SD) versus non-screen detected (NSD) colorectal cancer (CRC). (2021) (0)
Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Stage II Colon Cancer (DYNAMIC Trial): Statistical Analysis Plan (2021) (0)
Assessing real-world outcomes in metastatic colorectal cancer with KRASG12C mutation. (2020) (0)
Overall survival in the FOXFIRE-SIRFLOX-FOXFIRE Global prospective randomized studies of first-line SIRT in patients with mCRC (2017) (0)
1670P Circulating tumor DNA (ctDNA) dynamics of response and resistance in BRAF V600E mutant (mt) metastatic colorectal (mCRC) and other cancers: Data from EVICT (erlotinib and vemurafenib in combination trial) (2022) (0)
Abstract PS6-35: Real world outcomes in elderly women with HER2 positive advanced breast cancer (2021) (0)
A multicentre analysis of the long-term outcomes of patients with localized rectal cancer treated with chemotherapy and/or radiotherapy alone due to medical inoperability or patient refusal. (2006) (0)
EE94 Health Economic Evidence for Adjuvant Chemotherapy in Stage II and III Colorectal Cancer: A Systematic Review (2022) (0)
CR25P FAILURE TO ATTEND FOLLOW UP APPOINTMENTS IN PATIENTS WITH COLORECTAL CANCER – HOW COMMONLY DOES IT OCCUR AND WHY? (2009) (0)
Establishing a Longitudinal Opioid Pharmacogenomic Registry for Cancer Patients: Feasibility and Acceptability. (2022) (0)
Impact of diabetes on clinicopathologic and genetic features of colorectal cancer formation. (2013) (0)
O-014Evaluation of depth of response within a volumetric model in patients with metastatic colorectal cancer: results of the SIRFLOX study (2016) (0)
Current state of radiomic research in pancreatic cancer: focusing on study design and reproducibility of findings. (2023) (0)
Oncology Setting' Therapy for Elderly Advanced Colorectal Cancer Patients in the Community Response to 'Disparities in the Use of Chemotherapy and Monoclonal Antibody (2013) (0)
AGENT: An open-label phase III study of arfolitixorin versus leucovorin in modified FOLFOX-6 for first-line treatment of metastatic colorectal cancer. (2020) (0)
Survival Outcomes in Metastatic Colorectal Cancer (CRC) with High-Level Microsatellite Instability (MSI-H) (2012) (0)
Initial experience of TAS-102 chemotherapy in Australian patients with Chemo-refractory metastatic colorectal cancer. (2021) (0)
Role for a Web-Based Intervention to Alleviate Distress in People With Newly Diagnosed Testicular Cancer: Mixed Methods Study (2022) (0)
Impact of Body Mass Index on Colorectal Cancer Treatment and Outcomes : Need for Prospective and Comprehensive Data. Authors' reply (2009) (0)
Exploring Survival Outcomes in Metastatic Colorectal Cancer Harboring KRAS A146 Mutations: Important Distinction or Simple Distraction? (2022) (0)
Abstract 4099: Doctor (2014) (0)
165P Real-world utilisation of upfront chemohormonal therapy in metastatic hormone-sensitive prostate cancer (2022) (0)
Abstract 2778: Combination of DNA mismatch repair status and MACC1 expression in patients with stage II colon cancer: The BIOGRID studies (2017) (0)
Blood test stops cancer return (2015) (0)
A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study (2023) (0)
Abstract P1-18-13: Impact of prior (neo)adjuvant trastuzumab exposure on the efficacy of HER2 targeted therapy for metastatic breast cancer (2020) (0)
Outcomes of isolated distant lymph node metastases in colorectal cancer. (2021) (0)
Abstract OT2-02-01: A 'real world' experience of CDK4/6 inhibition with ribociclib and endocrine therapy in hormone receptor positive metastatic breast cancer in Australia (2020) (0)
Dual MAPK and HDAC inhibition rewires the apoptotic rheostat to trigger colorectal cancer cell death (2021) (0)
Answering real-world questions using real-world data: Understanding dynamic treatment decisions and outcomes in metastatic colorectal cancer (mCRC). (2019) (0)
151P Neoadjuvant and adjuvant chemotherapy in muscle-invasive bladder cancer: Real-world analysis of chemotherapy use and impact on patient outcomes (2022) (0)
602Prevalence of cancer history and association with risk factors in a healthy older population (2021) (0)
Insights into the SIRFLOX study. (2016) (0)
Real‐world use of first‐generation antiandrogens: impact on patient outcomes and subsequent therapies in metastatic castration‐resistant prostate cancer (2021) (0)
How accurate are medical oncologists’ impressions of management of metastatic colorectal cancer in Australia? (2018) (0)
PS1-2 Pembrolizumab vs chemotherapy for MSI-high/dMMR metastatic colorectal cancer: Asia subgroup of phase 3 KEYNOTE-177 (2021) (0)
Circulating tumour DNA in early stage colorectal cancer: can blood tell all? (2019) (0)
Treatment and outcomes of unresectable and metastatic pancreatic cancer treated in public and private Australian hospitals (2021) (0)
Associations between Metformin and Aspirin Use on Cancer Incidence and Mortality in Older Adults (2021) (0)
Medically actionable pathogenic variants in a population of 13,131 healthy elderly individuals (2020) (0)
Quality of life in patients with liver metastases from colorectal cancer treated with first-line selective internal radiotherapy (SIRT): EQ-5D, EORTC QLQ-C30 and LMC21 results from the FOXFIRE study (2017) (0)
Examining progression-free survival in first- and second-line treatment for BRAF-mutant metastatic colorectal cancer (CRC) (2017) (0)
Distress in People with Newly Diagnosed Testicular Cancer – Role for an Online Intervention to Alleviate Distress? (Preprint) (2022) (0)
NEOADJUVANT BIOCHEMOTHERAPY FOR STAGE I AND RESECTABLE STAGE IV MALIGNANT MELANOM (MM) (1999) (0)
Prognostic value of chronic inflammatory cell infiltrates in Duke's stage B and C colorectal cancer. (2010) (0)
Clinicopathologic and molecular associations of PIK3CA and PTEN mutation in colorectal cancer. (2012) (0)
S100 family proteins are linked to organoid morphology and EMT in pancreatic cancer (2023) (0)
Preoperative blood parameters as biomarkers for high-grade gliomas. (2010) (0)
Health economic evidence for adjuvant chemotherapy in stage II and III colon cancer: a systematic review (2023) (0)
Irinotecan-based regimens in combination with therapeutic antibodies formulated with hyaluronan (HA): a pre-clinical evaluation (2007) (0)
HSD76 Process Mining to Estimate Treatment Cost for the Entire Episodes of Colorectal Cancer Care Using Linked Data (2022) (0)
Real-World Outcomes in Patients With Brain Metastases Secondary to HER2-Positive Breast Cancer: An Australian Multi-centre Registry-based Study. (2022) (0)
Can neutrophil-to-lymphocyte ratio be used to identify patients with metastatic renal cell carcinoma who may gain greater benefit from cytoreductive nephrectomy? (2015) (0)
FORECAST-1: Feasibility of organoid response assessment to define effective treatments for patients with colorectal cancer after failure of standard therapy. (2021) (0)
P-063Effect of age on treatment effect and tolerability of SIRT when added to mFOLFOX chemotherapy in patients with metastatic colorectal cancer (mCRC) – results from the SIRFLOX study (2016) (0)
Second primary cancers in patients with sporadic deficient mismatch repair (dMMR) colorectal cancer (CRC). (2021) (0)
“Nothing to lose and the possibility of gaining”: a qualitative study on the feasibility and acceptability of registry-based randomised controlled trials among cancer patients and clinicians (2023) (0)
Use and outcomes from neoadjuvant chemotherapy in borderline resectable pancreatic ductal adenocarcinoma in an Australasian population (2022) (0)
CR26P LAPAROSCOPIC HYBRID RECTAL RESECTION FOR RECTAL CANCER (2009) (0)
CART-WHEEL.org: An Ethically Approved Online Database for Patient-Entered Data to Facilitate Rare Cancer Research (2020) (0)
Learning through clinical trials: 2013 and 2014 Preceptorship in Colorectal Cancer (CRC): an initiative of the Australasian Gastro-Intestinal Trials Group (AGITG) (2014) (0)
A real-world registry to evaluate HER2-directed therapy in Australian patients with metastatic breast cancer (MBC). (2017) (0)
Prognostic significance of albumin level in patients undergoing elective surgery for colon cancer (2008) (0)
Author reply (2021) (0)
Author reply (2013) (0)
2160 GIV as a novel marker of recurrence risk in MMR proficient stage II colon cancer (2015) (0)
1609 Final results from PAVES, a phase 3, randomized, double-blind, placebo-controlled trial of pegfilgrastim in patients (pts) receiving first-line FOLFOX or FOLFIRI and bevacizumab for locally advanced or metastatic colorectal cancer (LA/mCRC) (NCT00911170) (2015) (0)
Colorectal cancer screening: ensuring benefits outweigh the risks (2008) (0)
Real-world outcomes for neoadjuvant capecitabine versus infusional 5-fluorouracil in the treatment of locally advanced rectal cancer. (2020) (0)
Stage-based variation in the impact of colon cancer surveillance. (2019) (0)
PSMA PET-CT use prior to systemic therapy in metastatic Castration-Resistant Prostate Cancer (mCRPC). (2022) (0)
225P Prostate cancer treatments and outcomes in the elderly: A retrospective analysis of an Australian real-world cohort (2020) (0)
Erratum: A direct comparison of cytolytic T-lymphocyte responses to Melan-A peptides in vitro: Differential immunogenicity of Melan-A27-35 and Melan-A26-35 (Melanoma Research (2000) 10:1 (21)) (2000) (0)
Response to "Disparities in the use of chemotherapy and monoclonal antibody therapy for elderly advanced colorectal cancer patients in the community oncology setting". (2009) (0)
Do assumptions in health economic evaluations hamper drug uptake? (2020) (0)
Resection of colorectal cancer (CRC) metastases in routine practice. (2014) (0)
Less Surgery, Improved Survival From Stage IV Colorectal Cancer? (2015) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Peter Gibbs?

Peter Gibbs is affiliated with the following schools:

University of Western Australia
Institute of Cancer Research
University of Hull
Flinders University
MD Anderson Cancer Center
University of Oxford
University of Melbourne
Stanford University

Peter Gibbs's Academic­Influence.com Rankings

Peter Gibbs's Degrees

Similar Degrees You Can Earn

Why Is Peter Gibbs Influential?

Peter Gibbs's Published Works

Published Works

What Schools Are Affiliated With Peter Gibbs?

Peter Gibbs's AcademicInfluence.com Rankings